KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash & Equivalents (2016 - 2026)

Esperion Therapeutics filings provide 9 years of Cash & Equivalents readings, the most recent being $167.9 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 15.95% to $167.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $167.9 million, a 15.95% increase, with the full-year FY2025 number at $167.9 million, up 15.95% from a year prior.
  • Cash & Equivalents hit $167.9 million in Q4 2025 for Esperion Therapeutics, up from $92.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $226.6 million in Q1 2024 to a low of $82.2 million in Q4 2023.
  • Median Cash & Equivalents over the past 5 years was $144.7 million (2024), compared with a mean of $147.7 million.
  • Biggest five-year swings in Cash & Equivalents: surged 76.01% in 2024 and later plummeted 54.54% in 2025.
  • Esperion Therapeutics' Cash & Equivalents stood at $208.9 million in 2021, then plummeted by 40.27% to $124.8 million in 2022, then plummeted by 34.08% to $82.2 million in 2023, then surged by 76.01% to $144.8 million in 2024, then grew by 15.95% to $167.9 million in 2025.
  • The last three reported values for Cash & Equivalents were $167.9 million (Q4 2025), $92.4 million (Q3 2025), and $86.1 million (Q2 2025) per Business Quant data.